Hledat klinickou studii
57 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
ŠVÝCARSKO
Suisse Alémanique
ZÜRICH
Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich
Institut für diagnostische und interventionelle Radiologie
SPOJENÉ KRÁLOVSTVÍ
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
RAKOUSKO
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
RAKOUSKO
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Un essai en double aveugle, randomisé et contrôlé par placebo évaluant l'efficacité et l'innocuité du BI 1015550 sur 52 semaines chez des patients atteints de maladie pulmonaire interstitielle fibrosante progressive - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Service de Pneumologie
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Une étude multicentrique, randomisée, en double aveugle, contrôlée par placebo, de phase 2 portant sur l'efficacité, l'innocuité et la tolérabilité du BMS-986278 chez des participants atteints de fibrose pulmonaire - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de pneumologie
NĚMECKO
Bayern
MÜNCHEN
chILD-EU_EAA: Stop exogenous allergic alveolitis in childhood (StopEAA) - Europäische, prospektive, multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Studie zur Implementierung eines Verfahrens für die tägliche Behandlung der exogen-allergischen Alveolitis (Phase II)
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Christiane Herzog Ambulanz
AUSTRÁLIE
Victoria
ADDRESS: NOT PROVIDED - AU
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU
RAKOUSKO
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
BULHARSKO
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
ČESKÁ REPUBLIKA
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Charles University - First faculty of medicine
National Centre for Treatment of Gaucher Disease
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MASTER-ANCA: Etude prospective multicentrique randomisée comparant l'arrêt ou la poursuite du traitement immunosuppresseur d'entretien des vascularites associées aux ANCA chez les patients en Insuffisance Rénale Terminale.
Institution: Information not provided - FR
FRANCIE
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
NĚMECKO
Nordrhein-Westfalen
MÜNSTER
Auswirkungen von N-Acetyl-L-Leucin auf die Niemann-Pick-Krankheit Typ C (NPC): Eine randomisierte, plazebokontrollierte, doppelblinde Crossover-Studie der Phase III
Universitätsklinikum Münster
Centrum für seltene Erkrankungen (ZSE) Münster
IZRAEL
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
ITÁLIE
CAMPANIA
NAPOLI
Valutazione dell'efficacia e del trattamento con Miglustat in pazienti affetti da malattia di Niemann-Pick di tipo c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
ITÁLIE
FRIULI VENEZIA GIULIA
UDINE
ENCORE : Studio di fase 3, multicentrico nazionale, open-label, randomizzato per valutare l'efficacia e la sicurezza di Genz-112638 in pazienti con patologia di Gaucher tipo 1 trattati con terapia enzimatica sostitutiva.
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
ITÁLIE
PUGLIA
BARI
Terapia combinata della crioglobulinemia mista HCV-correlata con Interferone-alpha pegilato, ribavirina e rituximab
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBANON
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
SLOVENSKO
Bratislavsky kraj
ADDRESS: NOT PROVIDED - SK
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
ELIKIDS: Estudio abierto, de dos cohortes (con y sin imiglucerasa) y multicéntrico para evaluar la farmacocinética (FC), seguridad y eficacia de eliglustat en pacientes pediátricos con enfermedad de Gaucher (EG) tipo 1 (EG1) y tipo 3 (EG3) -ES
Institution: Information not provided - ES
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
TransportNPC: Estudio fase 3, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo, para evaluar la seguridad, la tolerabilidad y la eficacia de 2000 mg/kg de Trappsol Cyclo (hidroxipropil-beta-ciclodextrina) y tratamiento estándar comparado con placebo y tratamiento estándar en pacientes con la enfermedad de Niemann-Pick de tipo C1 -ES
Institution: Information not provided - ES
ŠVÝCARSKO
Suisse Alémanique
BERN
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH
Universitätsspital Inselspital
University Hospital Inselspital
TUNISKO
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURECKO
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
SPOJENÉ KRÁLOVSTVÍ
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
SPOJENÉ KRÁLOVSTVÍ
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
Institution: Information not provided - US
RAKOUSKO
WIEN
ADDRESS: NOT PROVIDED - AT
OCEAN: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy - AT
Institution: Information not provided - AT
FRANCIE
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN: Etude prospective, multicentrique, contrôlée, randomisée, évaluant une administration prolongée de prednisone en traitement d'entretien dans les vascularites systémiques associées aux ANCA.
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANCIE
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Programme d'accès à long terme au mépolizumab pour les sujets ayant participé à l'étude MEA115921 (étude du mépolizumab dans le traitement de la granulomatose éosinophilique avec polyangéite chez des sujets recevant un traitement de référence) - FR
Institution: Information not provided - FR
FRANCIE
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation d'une nouvelle stratégie de traitement de patients atteints de polyangéite microscopique, périartérite noueuse ou syndrome de Churg-Strauss sans facteur de pronostic défavorable (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
NĚMECKO
Baden-Württemberg
MANNHEIM
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
NĚMECKO
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Langzeitzugangsprogramm für Probanden, die an der Studie MEA115921 (Placebo-kontrollierte Studie von Mepolizumab zur Behandlung von eosinophiler Granulomatose mit Polyangiitis bei Probanden mit Standardtherapie) teilgenommen haben. - DE-
Institution: Information not provided - DE
NĚMECKO
Berlin
BERLIN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Charité - Universitätsmedizin Berlin
NĚMECKO
Nordrhein-Westfalen
ESSEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Essen
NĚMECKO
Nordrhein-Westfalen
MÜNSTER
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Münster
NĚMECKO
Sachsen
DRESDEN
Eine randomisierte, doppelblinde, Double-Dummy, aktiv kontrollierte, multizentrische, 2-teilige Phase-II-Studie zum Ersatz von Steroiden durch IFX-1 bei aktiver Granulomatose mit Polyangiitis (GPA) und mikroskopischer Polyangiitis (MPA)
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
NĚMECKO
Thüringen
JENA
NIZOZEMSKO
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
ŠPANĚLSKO
Cataluña
BARCELONA
ABROGATE: Abatacept (CTLA4-Ig) para el tratamiento de la recaída no grave de granulomatosis con poliangeítis (Wegener)
Hospital Clínic de Barcelona
ŠPANĚLSKO
Madrid
ADDRESS: NOT PROVIDED - ES
OCEAN: Un estudio de 52 semanas, aleatorizado, doble ciego, con doble simulación, de grupos paralelos, multicéntrico, de no inferioridad para investigar la eficacia y seguridad de depemokimab en comparación con mepolizumab en adultos con granulomatosis eosinofílica con poliangeítis (EGPA, por sus siglas en inglés) recidivante o refractaria que reciben el tratamiento habitual -ES
Institution: Information not provided - ES
SPOJENÉ STÁTY
Washington
ADDRESS: NOT PROVIDED - US
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Institution: Information not provided - US
Nadnárodní klinické studie
KANADA
Alberta
MOUNTAIN VIEW
NIZOZEMSKO
Utrecht
ADDRESS: NOT PROVIDED - NL
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (Phase III) (Coordination)
Institution: Information not provided - NL
NIZOZEMSKO
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
NIZOZEMSKO
Zuid-Holland
LEIDEN
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis
LUMC - Leids Universitair Medisch Centrum
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Oxfordshire
BEGBROKE
SPOJENÉ STÁTY
Massachusetts
CAMBRIDGE
SPOJENÉ STÁTY
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
ŠVÝCARSKO
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A phase IIa, international, multicentre, open-label, uncontrolled study to evaluate the safety and pharmacokinetics of 4× 375 mg/m2 intravenous rituximab in paediatric patients with severe granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis
Institution: Information not provided - CH
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy (Phase III)
Institution: Information not provided - GB
SPOJENÉ KRÁLOVSTVÍ
Greater London
ADDRESS: NOT PROVIDED - GB